Systemic Lupus Erythematosus Clinical Trial
Official title:
Care Coordination Approaches to Learning Lupus Self-management
The Care-coordination Approach to Learning Lupus Self-Management (CALLS) study was designed to examine whether modeling and reinforcement from a lay patient navigator/care coordinator improves disease self-management, indicators of disease activity, health related quality of life (HRQOL), and 30-day readmission in SLE inpatient admissions. We recruited 30 patients (~15 questionnaires and phone sessions and 15 questionnaires only) with active SLE upon hospital admittance at the Medical University of South Carolina (MUSC). The lay patient navigator/care coordinator was trained to deliver intervention content by twelve weekly telephone sessions carried out across the course of the study. All participants were assessed using validated measures of patient reported outcomes at baseline, mid-intervention (6 weeks post-enrollment), and immediately following the intervention (12 weeks post-enrollment). Outcomes for patients who agreed to phone sessions were compared with the outcomes of patients who opted to participate in questionnaires only. The study lasted 12 months, with recruitment and enrollment over 6 months, 3 months for intervention delivery and 3 months for data analysis.
Overview of Study Design. The Care-coordination Approach to Learning Lupus Self-Management
(CALLS) study is a double arm, pre-post pilot designed to examine whether modeling and
reinforcement from a lay patient navigator/care coordinator improves disease self-management,
indicators of disease activity, health related quality of life (HRQOL), and 30-day
readmission in SLE inpatient admissions. We will recruit 40 patients (20 questionnaires and
phone sessions and 20 questionnaires only) with active SLE upon hospital admittance at the
Medical University of South Carolina (MUSC). The lay patient navigator/care coordinator will
be trained to deliver intervention content by twelve weekly telephone sessions carried out
across the course of the study. All participants will be assessed using validated measures of
patient reported outcomes at baseline, mid-intervention (6 weeks post-enrollment), and
immediately following the intervention (12 weeks post-enrollment). Outcomes for patients who
agree to phone sessions will be compared with the outcomes of patients who opt to participate
in questionnaires only. The study will last 12 months with recruitment and enrollment over 6
months, 3 months for intervention delivery and 3 months for data analysis.
Study Population. The target population for this study will be SLE inpatient admissions at
MUSC. There are approximately 35 SLE and Scleroderma hospital admissions each month, so it is
expected that over a 3-month recruitment period, we will be able to recruit 40 participants
(20 questionnaires and phone sessions and 20 questionnaires only).
Recruitment of Lay Patient Navigator/Care Coordinator The PI will identify a suitable lay
patient navigator/care coordinator based on their maturity, emotional stability, and verbal
communication skills. Suitable candidates will have at least a high school diploma or
equivalency with at least one year of patient care experience in a health care facility; or a
Certified Nursing Assistant; or successful completion of a Nursing Assistant or Medical
Assistant course at an accredited institution or equivalent training; or EMT or Paramedic
certification; or a Bachelor's degree. They will possess the ability to understand and
implement a variety of detailed instructions in the execution of therapeutic procedures and
the ability to make accurate physical observation of patients.
Recruitment of SLE patients Admitted SLE patients will be referred by their physician for
participation in the study, who will provide a letter that will explain the study and provide
participants a number to call if they have questions or concerns prior to agreeing to
participate. Participants who indicate interest in the study will be immediately screened for
eligibility, and if eligibility criteria are met, informed consent will be obtained. Once a
patient has been consented, they will be randomized to membership in one of the two study
arms. assigned to the intervention (complete questionnaires and phone sessions) or control
(complete questionnaires only) arm, and the rest of the recruitment visit will include
baseline self-report assessments and scheduling of phone sessions (if applicable).
Phone sessions: The CALLS program will focus on enhancing the health of SLE patients, with
emphasis on patient empowerment and promoting proactive participation in health care.
Recruitment and enrollment will occur on a rolling basis, and the program will consist of 12
weeks of service delivery that will include one standard educational session by telephone or
in-person meeting every week. The weekly educational session will be generally structured in
three parts: introduction, structured education, and problem solving. Weekly content will be
adapted from the twelve modules of the Peer Approaches to Lupus Self-management (PALS) study,
and further tailored according to prominent barriers to care in the scientific literature.
Content will include: 1) Medication adherence; 2) Communication with provider; 3) Patient
engagement; 4) Recognizing and treating depression; 5) Overcoming socioeconomic barriers; 6)
Social Support network; 7) Appointment/ Lab adherence; and 8) Transportation. The lay patient
navigator/care coordinator will respond to individual patient needs by tailoring intervention
content to personal requirements and facilitating care coordination and will be able to
address insurance, financial, and logistical issues (e.g., transportation, appointment
scheduling, child or elder care), while providing understandable health education that may
lessen fears of SLE diagnosis and treatment. Lay patient navigator/care coordinator
activities will be guided by frequent self-report assessments, which will help to identify
patient concerns across multiple domains, triage patients to appropriate resources, and
ultimately overcome barriers to health care. The lay patient navigator/care coordinator can
use baseline data collected prior to phone sessions to describe preliminary patient themes
(i.e., disease activity and damage, depression, medication adherence, communication with
provider, patient engagement) and subsequent assessments can be used to track progress.
Data Collection Schedule. Study questionnaires were carefully chosen based on available
evidence of previous validation and their ability to measure key elements of the study aims.
The primary method of data collection will be face-to-face interview. All study visits will
take place in an MUSC affiliated hospital, the Research Nexus or comparable private location
on the campus of MUSC. Indicators of medication adherence will be extracted from the
electronic medical records. Financial data will be extracted from the research data warehouse
for historical and patient-specific data for cost effectiveness. The MUSC REDCap system will
be used for data management.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |